Age-Related Synaptic Dysfunction and Possible Approaches to Treatment
Dysfunction of the synaptic connections between neurons in the brain is characteristic of aging and exaggerated in neurodegenerative conditions, particularly Alzheimer's disease. The brain is a collection of neural networks: a neuron extends branching axons that connect to other neurons via synapse structures. When synapses lose function, the network loses function, and cognitive decline is the result. Here, researchers discuss the biochemistry of synapses and a variety of approaches to therapy that might improve matters. They conclude that the most promising approaches at the present time are those focused on reducing the impact of aging on the function of glial cells. Glia in the brain (microglia, astrocytes, and so forth) support the function of neural networks in a broad variety of ways, and their progressive dysfunction is considered an important contribution to age-related issues in axons and synapses.
Disturbances in synaptic transmission, particularly those that imbalance excitatory and inhibitory synapses, contribute to neuronal excitotoxicity in neurodegenerative diseases (NDDs). Such disorders are manifested explicitly in NDD pathology on various components of synaptic transmission, including presynaptic and postsynaptic receptors, along with their modulators. The current repertoire of anti-NDD drugs employed in clinical practice, which specifically target synaptic transmission, may offer a novel therapeutic avenue. However, the intricate mechanisms regulating synaptic transmission in health and disease remain to be elucidated.
In the treatment of NDDs, early screening for risk factors and prophylactic administration of drugs that regulate synaptic transmission homeostasis offer valuable options. Neuronal loss in NDDs may represent a downstream effect of pathogenic factors such as pathological protein aggregation and glial activation. Therefore, therapies that combine upstream pathophysiology, such as anti-amyloid-β antibodies, may provide a more effective solution. Clinical application of amyloid-β antibodies, postsynaptic neurotransmitter modulators, and neuroglia regulators may provide effective early intervention strategies for AD. In particular, glial regulators provide a theoretical basis for drug development through targeted regulation of lipid metabolism and enhancement of the autophagosome-lysosome system.
Finally, neuroinflammation orchestrates synaptic loss while concurrently reducing amyloid levels via the complement cascade. Therapeutic interventions that prevent synaptic transmission impairment and modulate glial-synapse interactions, such as complement inhibitors and TREM2 agonists, hold promise for altering the progression of NDDs. Given the multifactorial complexity of NDD pathophysiology, early glial-synapse targeting may effectively complement current treatments.